Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK933776 for SQ administration · 1 trial · 1 indication
Bioavailability is defined as the rate and extent to which drug reaches the systemic circulation. The relative bioavailability will be calculated from the ratio of area under concentration time curve from time zero to infinity (AUC \[0-infinity\]) following single dose SQ and IM injection to intravenous (IV) infusion
Bioavailability is defined as the rate and extent to which drug reaches the systemic circulation. The relative bioavailability will be calculated from the ratio of AUC (0-infinity) following SQ repeat dose injections to intravenous (IV) infusion
| Arm | Type | Description |
|---|---|---|
| Arm A | ACTIVE_COMPARATOR | Participants in this arm will receive single 200 milligram (mg) dose of GSK933776 administered by IV infusion |
| Arm B | EXPERIMENTAL | Participants in this arm will receive single 200 mg dose of GSK933776 administered SQ |
| Arm C | EXPERIMENTAL | Participants in this arm will receive 50 mg dose of GSK933776 administered SQ once weekly for 4 weeks (total dose = 200 mg). |
| Arm D | EXPERIMENTAL | Participants in this arm will receive single 200 mg dose of GSK933776 administered IM |
| Name | Type | Description |
|---|---|---|
| GSK933776 for SQ administration | DRUG | Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks |
| GSK933776 for IM administration | DRUG | Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose |
| GSK933776 for IV administration | DRUG | Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour |
Inclusion Criteria: * Male or female subject 18 to 50 years of age at the time of signing the informed consent * In general good health as determined by a physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject wit...
GSK933776 is an investigational small molecule being studied for geographic atrophy, an advanced form of age-related macular degeneration that causes progressive vision loss. It is administered subcutaneously and is being developed by GSK plc as a potential treatment for this ophthalmologic condition.
GSK933776 is being developed by GSK plc, a global biopharmaceutical company listed on the London Stock Exchange under the ticker GSK. The drug is an investigational small molecule in the ophthalmology therapeutic area, currently in clinical development for geographic atrophy.
GSK933776 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and pharmacokinetics in clinical trials.
GSK933776 has one completed Phase 1 clinical trial, identified as NCT02033668. This was a pharmacokinetic study conducted in healthy volunteers in the United States, with 36 participants enrolled. The study was randomized and actively controlled, and it evaluated the drug's pharmacokinetic profile.
GSK933776 is the name used in clinical development for this investigational small molecule. No alternative names have been reported for this drug in the available clinical trial information.